To improve the availability and effectiveness of medicines in the Netherlands, the UMCG is going to set up the company G2 Solutions.
This company must ensure that important technological developments in the field of DNA sequencing and stem cell models become profitable so that they can be further developed.
A subsidy of 5.7.million euros has been made available for this from the National Growth Fund.
View the full article at UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling (in Dutch)
